You are here: Home / Sites / Brigham and Womens Hospital / Cramer, Daniel

Cramer, Daniel (M.D., Sc.D.)

PI, Brigham and Womens Hospital, (617) 732-4895

Contact Information

Email: mailto:dcramer@partners.org
Fax: (617) 732-4899
EDRN Associate Member
OB/Gyn Epidemiology

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
Pre-operative plevic mass study 0 0

Closed Protocols

Protocol Name Biomarkers Datasets
Antibodies Against Tumor Antigens or Mucin Epitopes in Ovarian Cancer 0 0
Biomarker Reference Sets for Cancers in Women 0 0
PLCO Ovarian Phase III Validation Study 50 1
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study 55 2
Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement 28 0
EDRN Resource Network Exchange 0 0
Ovarian Cancer Screening Pilot Trial In High Risk Women 0 0

Publications

Publication Name PubMed ID Journal
Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer. 17245808 J Bioinform Comput Biol
Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. 16428483 Clin. Cancer Res.
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. 11584061 J. Natl. Cancer Inst.
Osteopontin as a potential diagnostic biomarker for ovarian cancer. 11926891 JAMA
Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. 12912935 Clin. Cancer Res.
Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. 18245537 Clin. Cancer Res.
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. 15894662 Cancer Epidemiol. Biomarkers Prev.
Non-genomic biomarkers of risk in ovarian cancer. 18057519 Dis. Markers
Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. 14581349 Clin. Cancer Res.
Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. 19008269 BMJ
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). 19282241 Lancet Oncol.
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. 18061248 Gynecol. Oncol.
A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. 18349277 Cancer Epidemiol. Biomarkers Prev.
Urokinase-type plasminogen activator receptor: a beacon of malignancy? 18794069 Clin. Cancer Res.
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. 15161704 Clin. Cancer Res.
Promoter hypermethylation profile of ovarian epithelial neoplasms. 16061849 Clin. Cancer Res.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.

Addresses

221 Longwood Ave., RFB 366
Brigham and Women's Hospital

To update addresses, please visit the Data Management and Coordinating Center.

Announcement 09/27/2019
Thank you to everyone who made the 11th EDRN Scientific Workshop a success. The next EDRN Steering Committee Meeting is from Tuesday-Thursday, March 31-April 2, 2020 in Tempe, AZ.
Announcement



 
This icon signifies that something is happening and we kindly ask you to please wait